Previous 10 | Next 10 |
PAVmed ([[PAVM]] -13.4%) inks agreement for the sale of 6.0M common stock at $2.24/share, priced at-the-market, in a registered direct offering.Total gross proceeds are expected to be ~$13.4M.Net proceeds from the offering are expected to be ~$12.4M. Maxim Group LLC is acting a...
NEW YORK, Jan. 06, 2021 (GLOBE NEWSWIRE) -- PAVmed Inc. (Nasdaq: PAVM, PAVMZ) (the “Company” or “PAVmed”), a highly differentiated, multi-product, commercial-stage medical device company, today announced it has entered into agreements for the sale of 6.0 mil...
PAVmed (PAVM) declares the closing of previously announced registered direct offering of ~5.1M shares of common stock at $1.60 per share.The company plans to use the net proceeds of ~7.4M for working capital, general corporate purposes, and partial repayment of its outstanding conve...
NEW YORK, Dec. 22, 2020 (GLOBE NEWSWIRE) -- PAVmed Inc. (Nasdaq: PAVM, PAVMZ) (the “Company” or “PAVmed”), a highly differentiated, multi-product, commercial-stage medical device company, today announced the closing of its previously announced registered direct o...
PAVmed ([[PAVM]] -3.6%) entered into agreements for the sale of ~5.1M shares in a registered direct offering with predominantly existing institutional investors at a price of $1.60/share for gross proceeds of $8.1M.Estimated net proceeds are expected to be ~$7.4M; offering expected to close o...
NEW YORK, Dec. 18, 2020 (GLOBE NEWSWIRE) -- PAVmed Inc. (Nasdaq: PAVM, PAVMZ) (the “Company” or “PAVmed”), a highly differentiated, multi-product, commercial-stage medical device company, today announced it has entered into agreements for the sale of approximatel...
PAVmed (PAVM) enters into agreements for the sale of 5.6M shares in a registered direct offering at a price of $1.60 per share for gross proceeds of ~$8.9M.Offering expected to close on or about December 15.Press Release For further details see: PAVmed offers stock for $8.9M
PAVmed, Inc. (PAVM) Q3 2020 Earnings Conference Call November 17, 2020 4:30 PM ET Company Participants Mike Havrilla – Director-Investor Relations Lishan Aklog – Chairman and Chief Executive Officer Dennis McGrath – President and Chief Financial Officer Conference Call Pa...
PAVmed (PAVM): Q3 Non-GAAP EPS of -$0.09 beats by $0.02; GAAP EPS of -$0.11 in-line.Cash and equivalents of $8.3M.Press Release For further details see: PAVmed EPS beats by $0.02
Conference call to be held today at 4:30 p.m. Eastern time NEW YORK, Nov. 17, 2020 (GLOBE NEWSWIRE) -- PAVmed Inc. (Nasdaq: PAVM, PAVMZ ) (the “Company” or “PAVmed”), a highly differentiated, multi-product, commercial-stage medical device company, t...
News, Short Squeeze, Breakout and More Instantly...
PAVmed to Hold a Business Update Conference Call and Webcast on August 13, 2024 PR Newswire Conference Call and Webcast at 8:30 AM Eastern Time NEW YORK , July 30, 2024 /PRNewswire/ -- PAVmed Inc. (Nasdaq: PAVM, PAVMZ ) ("PAVmed" or the "C...
Lucid Diagnostics to Hold a Business Update Conference Call and Webcast on August 12, 2024 PR Newswire Conference Call and Webcast at 8:30AM Eastern Time NEW YORK , July 29, 2024 /PRNewswire/ -- Lucid Diagnostics Inc. (Nasdaq: LUCD) ("Luc...
Lucid Diagnostics Announces Record Quarterly EsoGuard® Test Volume PR Newswire Quarterly EsoGuard ® test volume increased 31 percent sequentially NEW YORK , July 23, 2024 /PRNewswire/ -- Lucid Diagnostics Inc. (Nasdaq: LUCD) ("L...